PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer

CHUNAN BIAN, ZONGHANG LIU, DAKOU LI and LIFENG ZHEN

Department of Cardiothoracic Surgery, Nanjing Jiangbei People’s Hospital, Nantong University, Nanjing, Jiangsu 210048, P.R. China

Received March 28, 2017; Accepted November 16, 2017

DOI: 10.3892/ol.2018.8587

Abstract. Constitutive activation of the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway is evident in a diverse array of human cancer types, and targeting the pathway is an attractive therapeutic approach. However, pre-clinical and clinical studies have demonstrated that the antitumor efficacy of a number of inhibitors of the PI3K/AKT pathway is poor, and the underlying mechanisms are not completely clear. In the present study, activation of MET proto-oncogene (MET)/signal transducer and activator of transcription 3 (STAT3) signaling was demonstrated during PI3K/AKT inhibition. Western blotting showed that the pharmacological or genetic inhibition of PI3K/AKT signaling triggered compensatory activation of STAT3 and upregulation of the expression of its downstream genes. The results from RTK array analysis and western blotting demonstrated that the hyperactivated STAT3 signaling was demonstrated to be mediated by the activation of MET. In addition, PI3K/AKT inhibition suppressed tumor growth more effectively when combined with inhibitors targeting MET/STAT3 signaling by detecting apoptosis and colony formation. These results were further confirmed in a nude mouse model. Thus, our results highlight a compensatory survival mechanism via the MET/STAT3 signaling pathway after PI3K/AKT signaling inhibition in non-small cell lung cancer.

Introduction

As the majority of elderly patients with lung cancer have a poor prognosis after treatment with either routine or large-dose chemotherapy (1), it is important to elucidate novel targeted therapies and immunotherapies to improve quality of life and prolong survival (2). Previous studies have investigated the signaling pathways that drive lung cancer progression and a number of targeted therapeutic strategies have been proposed (3,4). However, long-term effectiveness of lung cancer treatment is rare and recurrence is promoted by various mechanisms, including compensatory activation of cell survival signaling pathways (5,6).

The phosphoinositide 3-kinase (PI3K) signaling pathway serves an important role in the regulation of cell proliferation, growth, survival and metabolism (7). Aberrant activation of the PI3K/AKT pathway has been observed in several types of cancer, including non-small cell lung cancer (NSCLC) (8,9). Hyperactivation of the PI3K/AKT pathway may be involved in the resistance to chemotherapeutic and targeted reagents in different cancer types through anti-apoptotic functions (10), making it a therapeutic target of cancer (11). Several small molecule inhibitors of the PI3K/AKT signaling pathway have undergone clinical trials in humans (12,13). Despite the great potential of such targeted therapies in lung cancer, a subset of patients exhibiting hyperactivation of PI3K/AKT signaling do not respond to these inhibitor drugs (13,14).

In the present study, it was demonstrated that inhibitors of the PI3K/AKT pathway activated the signal transducer and activator of transcription 3 (STAT3) signaling pathway. Previous studies have demonstrated that persistent activation of the STAT3 signaling pathway is associated with various types of solid cancer (15,16). While STAT3 hyperactivation has been demonstrated to mediate drug resistance (17), inhibition of the STAT3 signaling pathway has been demonstrated to reverse drug resistance (18). The aim of the present study was to identify the molecular determinants driving the compensatory activation of STAT3 after treatment with PI3K/AKT inhibitors, which may limit the clinical efficacy of these compounds. The results suggest novel cross-talk between the PI3K/AKT and STAT3 signaling pathways, modulated by the MET proto-oncogene (MET). Targeting MET/STAT3 signaling potentiates the antitumor activity of PI3K/AKT inhibitors, and may be an effective therapeutic strategy for NSCLC.

Materials and methods

Cell lines, reagents and transfection. The NSCLC cell lines, H460 and H2126, were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). The 2 cell
lines were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin (all from HyClone; GE Healthcare, Chicago, IL, USA) at 37°C with 5% CO₂, BKM120 (a selective PI3K inhibitor; S2247), LY294002 (a pan-PI3K inhibitor; S1105), MK-2206 (an AKT allosteric inhibitor; S1078), BEZ235 [a dual PI3K/mechanistic target of rapamycin (mTOR) catalytic inhibitor; S1009], PF-2341066 (a MET inhibitor; S1068) and stattic (a STAT3 inhibitor; S7024) were obtained from Selleck Chemicals (Houston, TX, USA), and dissolved in DMSO. Specific small interfering RNAs (siRNAs) for p110α (si-p110α; 100 nM; cat. no. 6359S), AKT (si-AKT; 100 nM; cat. no. 6211S) and MET (si-MET; 100 nM; cat. no. 6618S) were obtained from Cell Signaling Technology Inc. (Danvers, MA, USA). Transfection was performed using Lipofectamine 2000® in Opti-MEM (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Cells were transfected with an individual siRNA or treated with an inhibitor for 24 h prior to subsequent experimentation.

Western blotting. Cell lysates of H460 and H2126 cells were prepared using radioimmunoprecipitation assay buffer (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) and protease inhibitors. Total protein concentration was determined by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). 12% Tricine‑SDS‑PAGE was used to separate 10 µg protein. Subsequent to transfer to a nitrocellulose membrane, the following primary antibodies were used: Phosphorylated-STAT3 (p-STAT3 Y705; cat. no. 9145; dilution 1:1,000), p-extracellular regulation kinase (p-ERK1/2, T202/Y204; 4376; dilution 1:1,000), p-AKT (S473; cat. no. 4060; dilution 1:1,000), p-AKT (T308; cat. no. 13038; dilution 1:1,000), p-S6 (S240/244; cat. no. 5364; dilution 1:1,000), p-MET (Y1349; cat. no. 3133; dilution 1:1,000), STAT3 (cat. no. 12604; dilution 1:1,000), ERK1/2 (p-ERK1/2, T202/Y204; 4376; dilution 1:1,000), AKT (cat. no. 4695; dilution 1:1,000), AKT (catalog no., 4685; dilution 1:1,000), p-MET (Y1349; cat. no. 3133; dilution 1:1,000) and MET antibodies (cat. no. 8198; dilution 1:50) for 1 h at 4°C. Anti-rabbit IgG F(ab')2 Fragment (Alexa Fluor® 594 Conjugate; cat. no. 8889; Cell Signaling Technology) was incubated with the cells for 30 min at 4°C. Fluorescence microscopy was used to examine the expression of p-MET and MET.

STAT3 DNA-binding activity assay. H460 and H2126 cells were treated with 1 µM BKM120 for 12 h, and the Pierce LightShift Chemiluminescent EMSA kit (Thermo Fisher Scientific, Inc.) was used to confirm that BKM120 increased STAT3 DNA-binding activity, as described previously (19).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from H460 and H2126 cells using TRIZol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) after 12 h of treatment with 0.1% dimethyl sulfoxide (DMSO), or 0.1 or 1 µM BKM120. The Maxima First Strand cDNA Synthesis kit (Thermo Fisher Scientific, Inc.) was used to obtain cDNA, which was used in reaction with GoTaq qPCR Master Mix with SYBR-Green (Promega Corporation, Madison, WI, USA) and primers specific for matrix metalloproteinase 9 (MMP9), B-cell lymphoma 2 (bcl-2), survivin, cyclin-D1, hepatocyte growth factor (HGF) and C-reactive protein (CRP). PCR included a 12 min denaturation step at 94°C, followed by 38 cycles of 94°C for 10 sec, 60°C for 20 sec and 71°C for 10 sec. GAPDH was used as endogenous control. Primers for these genes were sourced from PrimerBank (http://pga.mgh.harvard.edu/primerbank/), and the sequences are as follows: MMP9 forward, 5'-TGT G GGCATCAATGGAATGG-3'; reverse, 5'-ACACA TGTATTCGGGGTCAAAT-3'; Bcl-2 forward, 5'-GGTGGG GTCTAGTGGTGGTG-3'; reverse, 5'-CGGTTCACTGTC TACATCC-3'; surviving forward, 5'-AGGACACCAGG CTTCTCTAC-3' and reverse, 5'-AGTCTGGGTCGTCG TCACTG-3'; cyclin-D1 forward, 5'-GCTGGCAAGTGGA AA CCATC-3' and reverse, 5'-CTCTCTCTCTGACACATTTG A-3'; HGF forward, 5'-GATCTCAGGTTGAAGCAGCTACA-3' and reverse, 5'-CTGATCGTGATTGGTGCA-3'; CRP forward, 5'-AACGGAACCCCTCAAGCCT-3' and reverse, 5'-CTCGTCTGGGCCATCGGAAAT-3'. The 2-∆∆Cq method was applied to present final results (20).

Receptor tyrosine kinase (RTK) array analysis. After 24 h of cell starvation in serum-free medium, the H460 cells were incubated for 12 h at 37°C in the absence (DMSO) or presence of BKM120 (1 µM). The mixture of proteins was prepared, and the phosphorylation status of each protein was examined by RTK array analysis. Array 001 (R&D Systems, Inc., Minneapolis, MN, USA) was used to detect tyrosine-phosphorylated RTKs, according to the manufacturer's instructions.

Cell apoptosis assay. H460 and H2126 cells were seeded at 2x10⁵ cells/well in 24-well plates and left overnight prior to treatment with DMSO [negative control (NC)], BKM120 (1 µM), PF-2341066 (1 µM) or stattic (5 µM) for 60 h. Cells were harvested by centrifugation (250 x g, 5 min, 4°C), washed once with PBS and resuspended in 1X fluorescence-activated cell sorting buffer (BD Biosciences, Franklin Lakes, NJ, USA) at 1x10⁶ cells/ml. The frequency of apoptosis was detected using the Alexa Fluor® 488 Annexin V/Dead Cell Apoptosis Kit (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions.
A clonogenic assay was performed where 300 cells were seeded in 6-well plates overnight and treated with DMSO (NC), BKM120 (1 µM), PF-2341066 (1 µM) or stattic (5 µM) and cultured for a further 14 days. The cell clones were fixed and stained with 0.05% crystal violet at room temperature for 15 min, and the number of clones was counted under an optical microscope.

**In vivo studies.** 5-week-old female BALB/c mice (Weitonglihua Biotechnology, Beijing, China) weighing 17-20 g were maintained in the pathogen-free animal facility under controlled conditions (12:12 h light and dark cycle, 50% humidity and 22°C). These animals were provided rodent chow and water. A total of 2x10^6 H460 cells were inoculated subcutaneously into the flank of the mice. The mice were randomly divided into 6 groups (n=10) when tumors reached a size of ~100 mm^3. The mice were treated with control [0.5% (w/v) aqueous dimethyl sulfoxide (DMSO) by oral gavage], BKM120 [15 mg/kg, in 0.5% (w/v) aqueous hydroxypropylcellulose solution by oral gavage], PF-2341066 [25 mg/kg, in 0.5% (w/v) aqueous hydroxypropylcellulose solution by oral gavage] or stattic [3 mg/kg, by intraperitoneal injection]. Each drug was administered daily. The tumors were measured using calipers and volume was calculated using the following formula: \( \text{Volume} = \frac{\text{Length} \times \text{Width}^2}{2} \). The procedures for care and use of animals were approved by the Ethics Committee of the Nanjing Jiangbei People’s Hospital (approval no. IACUC/201606B03; Nanjing, China).

**Statistical analysis.** Data are presented as the mean ± standard error (SE). Multiple group comparisons of the means were performed by one-way analysis of variance and post-hoc Student-Newman-Keuls test. *P<0.05, **P<0.01 and ***P<0.001, compared with the DMSO control group.

**Results**

Inhibition of PI3K/AKT signaling causes STAT3 activation. H460 and H2126 cells were treated with the selective PI3K inhibitor, BKM120. BKM120 markedly inhibited p-AKT at Ser473 and Thr308, and a dose-dependent increase in p-STAT3 was observed, whereas the phosphorylation of ERK1/2 remained unchanged (Fig. 1A). BKM120 also demonstrated mTORC1 inhibitory activity, which is evident from the reduction of p-S6 with the increasing concentration of BKM120.

A number of different PI3K/AKT inhibitors were used to confirm the activation of STAT3 by pharmacological inhibition of the PI3K/AKT pathway. Fig. 1B demonstrates the elevated expression of p-STAT3 with the treatment with all reagents, including LY294002 (pan-PI3K inhibitor), MK-2206 (AKT inhibitor) and BEZ235 (a dual p110/mTOR inhibitor).
To eliminate the possibility that these results were due to off-target pharmacological effects of the inhibitors, PI3K/AKT signaling was silenced via p110α or AKT using 2 different target-specific siRNAs. Silencing of p110α or AKT resulted in markedly enhanced activation of STAT3, and decreased AKT activity in the si-AKT group (Fig. 1C).

The STAT3 DNA-binding activity increased in H460 and H2126 cells with the concentration of BKM120 treatment (Fig. 1D). STAT3-dependent transcriptional activity was examined by detecting the expression of STAT3 downstream target genes, including MMP9, bcl-2, survivin, cyclin-D1, HGF, CRP and bcl-2 family apoptosis regulator (Mcl-1) (21). As demonstrated in Fig. 1E, treatment with BKM120 increased the expression of all genes, except Mcl-1. Taken together, these results suggest that the pharmacological or genetic inhibition of PI3K/AKT signaling triggered compensatory activation of STAT3 and altered its downstream signaling events.

PI3K/AKT signaling inhibition induces MET expression and activation. The regulatory mechanism behind the compensatory activation of STAT3 induced by PI3K/AKT inhibition was further investigated. Since multiple RTKs were involved in the activation of STAT3 signaling, the phosphorylation level of RTKs was detected in BKM120-treated H460 cells using a RTK array. Elevated p-MET was observed in H460 cells with BKM120 treatment (Fig. 2A).

In consensus with these results, western blot analysis demonstrated that BKM120 treatment upregulated the expression levels of p-MET and total MET protein (Fig. 2B), which was further corroborated by IF (Fig. 2C). In order to elucidate the function of MET in regulating the activation of STAT3 signaling following PI3K/AKT inhibition, MET expression was silenced by transfection with specific siRNA (si-MET). The results demonstrate that the depletion of MET resulted in inhibition of p-STAT3, as well as a modest suppression of p-AKT (Fig. 2D). Taken together, these results suggest that PI3K/AKT inhibition may activate STAT3 signaling via upregulating the expression and activation of MET.

MET/STAT3 inhibition promotes the pro-apoptotic and anti-proliferative effects of PI3K/AKT inhibitors. To investigate the compensatory activation of the MET/STAT3 pathway as a resistance mechanism to PI3K/AKT targeted therapy, the antitumor efficacy of PI3K/AKT inhibitors was evaluated when MET/STAT3 signaling was inhibited. As demonstrated in Fig. 3A, MET inhibition markedly abrogated STAT3 phosphorylation and AKT activity, and STAT3 inhibition completely abrogated BKM120-induced activation of STAT3. Antitumor efficacy was observed of BKM120 alone, and its potency increased in combination with PF-2341066 or statitic. This was indicated by increased apoptosis of tumor cells treated with the inhibitor combination compared...
with those treated with each inhibitor singly (Fig. 3B). A significant decrease in colony number was also observed when cells were treated with BKM120 in combination with PF-2341066 or stattic compared with cells treated with a single inhibitor (Fig. 3C).

**Discussion**

PI3K/AKT signaling is a core regulatory mechanism in cancer cells. Hyperactivation of the signaling pathway is evident in NSCLC, and is therefore a therapeutic target for the disease (22,23). Small molecule inhibitors of this pathway are a focus in current research, and demonstrate potential applications in targeted therapy (24). However, the compensatory activation of other pathways is a major limitation in the feasibility and effectiveness of these small-molecule inhibitors. It has been reported that inhibition of the PI3K signaling pathway leads to enhanced ERK signaling in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (25). The WNT/β-catenin pathway, neurogenic locus notch homolog protein 1 and eukaryotic translation initiation factor 4E have been demonstrated to mediate PI3K inhibitor resistance (26-28). In the present study, enhanced activation of MET/STAT3 signaling following PI3K/AKT inhibition was demonstrated in NSCLC.

Persistent STAT3 signaling has been demonstrated to promote cancer progression through assisting proliferation, metastasis, angiogenesis and resistance to various drugs (17,18).
In the present study, multiple PI3K/AKT inhibitors induced the activation of the STAT3 signaling pathway, including BKM120 (an inhibitor of PI3K), LY294002 (a pan-AKT inhibitor), MK2206 (an AKT allosteric inhibitor) and BEZ235 (a dual PI3K/mTOR catalytic inhibitor) (Fig. 1A and B). Knocked down expression of PI3K subunit p110α and AKT by siRNA increased the protein expression level of p-STAT3 (Fig. 1C). Acquired ERK dependency has been reported in HER2-overexpressing breast cancer following PI3K inhibition (25). However, no difference in the phosphorylation of...
ERK1/2 was observed after PI3K/AKT inhibition in the present study. PI3K/AKT inhibition did result in the overexpression of several STAT3 target genes, including MMP9, bcl-2, survivin, cyclin-D1, HGF and CRP (Fig. 1E). Collectively, these results suggest novel cross-talk between the PI3K/AKT and STAT3 pathways, and the compensatory activation of STAT3 may limit the clinical application of PI3K/AKT inhibitors in cancer treatment.

Activation of RTKs is a key event in signal transduction and regulates multiple pathways, including PI3K/AKT and STAT3 signaling (29). An RTK array was used to study the effects of BKM120 administration on the activation status of RTKs, and indicated a high level of tyrosine phosphorylation of MET subsequent to PI3K/AKT signaling inhibition (Fig. 2A). These results were further confirmed by western blotting and IF (Fig. 2B and C). Genetic or pharmacological inhibition of MET disrupted PI3K inhibition-induced STAT3 activation (Fig. 2D), indicating that STAT3 signaling was regulated by MET. MET encodes an RTK and has been indicated to function as an oncogene (30). Amplification of MET has been demonstrated to contribute to tumorigenesis in multiple types of human cancer (31,32). Numerous studies have demonstrated that MET-mediated STAT3 signaling is involved in tumor cell growth and survival, as well as in tumor metastasis (33,34). A recent study demonstrated that MET-STAT3 signaling was a potential mechanism of resistance to MEK1/2 inhibitors in colorectal cancer originating from KRAS mutations (35).

Since compensatory activation of the MET/STAT3 signaling pathway may be involved in the failure of PI3K/AKT inhibitor treatment in clinical trials, alternative therapeutic strategies against NSCLCs were also explored in the present study. MET and STAT3 inhibitors not only inhibited STAT3 phosphorylation but also increased the pro-apoptotic and anti-proliferative effects of PI3K inhibitors in vitro (Fig. 3). These results were also obtainable in lung cancer-bearing nude mice (Fig. 4). This suggests the administration of PI3K inhibitors in combination with either MET or STAT3 inhibitors as a potential therapeutic strategy to replace monotherapy (Fig. 4E).

In conclusion, the present study highlights the role of MET/STAT3 signaling as a compensatory response to PI3K/AKT blockade, suggesting dual inhibition of PI3K/AKT and MET/STAT3 pathways as an effective NSCLC therapy. Further studies will be required to validate these results in clinical tumor samples. It may be a useful to consider the MET/STAT3 activation state in targeted therapy against NSCLC.

References
1. Blanco R, Maestu I, de la Torre MG, Cassinello A and Nunez I: A review of the management of elderly patients with non-small-cell lung cancer. Ann Oncol 26: 451-463, 2015.
2. Naylor EC, Desani JK and Chung PK: Targeted therapy and immunotherapy for lung cancer. Surg Oncol Clin N Am 25: 601-609, 2016.
3. Yang L, Li G, Zhao L, Pan F, Qiang J and Han S: Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive non-small-cell lung cancer. Tumour Biol 35: 9759-9767, 2014.
4. Sorredella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
5. Gadepalvi VS, Deb SP, Deb S and Rao RR: Lung cancer stem cells, p53 mutations and MDM2. Sabcell Biochem 85: 359-370, 2014.
6. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancemaster JM, Berchuck A, et al: Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357, 2006.
7. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
8. Baselga J: Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16 (Suppl 1): S12-S19, 2011.
9. Engelman JA: The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 13: s437-s440, 2007.
10. Xu H, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, et al: Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int J Cancer 122: 433-443, 2008.
11. Liu P, Cheng H, Roberts TM and Zhao J: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644, 2009.
12. Brana I and Siu LL: Clinical development of phosphatidylinositol-3-kinase inhibitors for cancer treatment. BMC Med 10: 161, 2012.
13. Seront E, Rottey S, Fillieul B, Glorieux P, Goeminne JC, Verschaeve V, Vandebulcke JM, Sautois B, Boegner P, Gillain A, et al: Phase II study of dual phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int 118: 408-415, 2016.
14. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britton CD, et al: A Phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res 21: 730-738, 2015.
15. Chen CL, Loy A, Cen L, Chan C, Hsieh FC, Cheng G, Wu B, Qualman SJ, Kunisada K, Yamauchi-Takihara K and Lin J: Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 7: 111, 2007.
16. Huang C, Wang L, Yang X, Lai L, Chen D and Duan C: Expression of activated signal transducer and activator of transcription-3 as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma. World J Surg Oncol 13: 314, 2015.
17. Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al: Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human lung cancer cells. Breast Cancer Res 12: 11-19, 2009.
18. Masciocchi D, Gelain A, Villa S, Meneghetti F and Barlocco D: Signal transducer and activator of transcription 3 (STAT3): A promising target for anticancer therapy. Future Med Chem 3: 367-397, 2011.
19. Rossey SL, Liao AT, McCleese JK, Bear MD, Lin J, Li PK, Kisseberth WC and London CA: Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer 9: 81, 2009.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2ΔΔCT method. Methods 25: 402-408, 2001.
21. Carpenter RL and Lo HW: STAT3 target genes relevant to human cancers. Cancers (Basel) 6: 897-925, 2014.
22. Martinez-Martí A and Felip E: PI3K pathway in NSCLC. Front Oncol 1: 55, 2011.
23. Heavey S, O’Byrne KJ and Gately K: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 40: 445-456, 2014.
24. Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaiga N, Sato M, Kikuzume T, Robson M, Quadt C and Doi T: Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 105: 347-353, 2014.
25. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandraratnap S, Markman B, Rodriguez O, Guzman M, Rodriguez S, et al: PI3K inhibition results in enhanced HER2 signaling and acquired KRK dependency in HER2-overexpressing breast cancer. Oncogene 30: 2547-2557, 2011.
26. Ilic N, Utermark T, Widlund HR and Roberts TM: PI3K-targeted therapy can be evaded by gene amplification along the MYC–eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 108: E699–E708, 2011.

27. Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfo S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, et al: β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 18: 892–901, 2012.

28. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, et al: Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med 17: 1116–1120, 2011.

29. He L and Hristova K: Quantification of the effects of mutations on receptor tyrosine kinase (RTK) activation in mammalian cells. Methods Mol Biol 1233: 81–87, 2015.

30. Birchmeier C, Birchmeier W, Gherardi E and Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915–925, 2003.

31. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, Jida M, Otani H, Fujii T, Ouchida M, et al: MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 124: 1778–1784, 2009.

32. Janbabai G, Oladi Z, Farazmandfar T, Taghvaei T and Naghshvar F: The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR. J Cancer Res Clin Oncol 141: 1945–1952, 2015.

33. Syed ZA, Yin W, Hughes K, Gill JN, Shi R and Clifford JL: HGF/c-met/Stat3 signaling during skin tumor cell invasion: Indications for a positive feedback loop. BMC Cancer 11: 180, 2011.

34. Zhang YW, Wang LM, Jove R and Vande Woude GF: Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21: 217-226, 2002.

35. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J et al: ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep 7: 1940-1955, 2014.